HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
about
Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs).Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects.
P2860
HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
@en
HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
@nl
type
label
HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
@en
HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
@nl
prefLabel
HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
@en
HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
@nl
P2093
P2860
P356
P1476
HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
@en
P2093
Adam Whaley Connell
Ganesh Athappan
Georges Saab
James R Sowers
L Romayne Kurukulasuriya
P2860
P356
10.1177/1753944707082714
P577
2007-10-01T00:00:00Z